Analyst Upgrades: Apple, Intercept Pharma, ACADIA Pharma

Analysts upwardly revised their ratings and price targets on Apple Inc. (AAPL), Intercept Pharmaceuticals Inc (ICPT), and ACADIA Pharmaceuticals Inc. (ACAD)

Mar 30, 2016 at 9:25 AM
facebook X logo linkedin

Analysts are weighing in on tech titan Apple Inc. (NASDAQ:AAPL), as well as biotech stocks Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Here's a quick roundup of today's bullish brokerage notes on AAPL, ICPT, and ACAD.
  • Cowen and Company upgraded AAPL to "outperform" from "market perform" and lifted its price target to $135 from $125 -- a 25% premium over Tuesday's close of 107.68, and in record-high territory, lifting the shares 1.2% ahead of the open. Apple Inc. has been in the spotlight this week since the FBI cancelled its hearing against the company and reported it was able to crack the iPhone in question, but there is still no word on whether AAPL will be informed of how its security measures were breached. The company also announced overnight that it will partner with the MLB to put an iPad in every team's dugout.
  • Credit Suisse initiated coverage on ICPT with an "outperform" rating and lofty $200 price target, while Goldman Sachs started coverage with a more tepid "neutral" rating. The stock is 2.2% higher in electronic trading, after settling at $124.26 on Tuesday. The shares have been bouncing between $115 and $130 since mid-February, and it looks like their overhead 80-day moving average could now be acting as resistance. If the stock can break out higher today, some bearish option traders may get nervous. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Intercept Pharmaceuticals Inc has a 10-day put/call volume ratio of 3.09 -- at the peak of its annual range.
  • ACAD is set to pop 21.4% at the open, as Tuesday's upbeat drug news was met with a price-target hike to $44 from $39 at Piper Jaffray. ACADIA Pharmaceuticals Inc. was halted at $23.81 for the entire session on Tuesday while an Food and Drug Administration (FDA) panel reviewed its Parkinson's disease psychosis (PDP) drug, Nuplazid. The encouraging outcome should have the stock shaking off a good portion of its 33% year-to-date loss today, especially if a short squeeze adds fuel to ACAD's fire. For example, it'd take short sellers more than eight sessions to cover their positions, at average daily volumes. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI